Review ArticleClinical Review

Understanding the Quality Chasm for Hypertension Control in Diabetes: A Structured Review of “Co-maneuvers” Used in Clinical Trials

Aanand D. Naik, Tim T. Issac, Richard L. Street and Mark E. Kunik
The Journal of the American Board of Family Medicine September 2007, 20 (5) 469-478; DOI: https://doi.org/10.3122/jabfm.2007.05.070026

References

  1. ↵
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Sowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med 2004; 164: 1850–7.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138: 593–602.
    OpenUrlCrossRefPubMedWeb of Science
  4. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720–6.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003; 26: 355–9.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J. Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. J Hum Hypertens 2003; 17: 37–44.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Kerr EA, Gerzoff RB, Krein SL, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med 2004; 141: 272–81.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112: 1651–62.
    OpenUrlFREE Full Text
  10. ↵
    Hart PD, Bakris GL. Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med 2004; 117: 62–4.
    OpenUrlCrossRefPubMed
  11. ↵
    Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383–6.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000; 160: 2281–6.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001; 135: 825–34.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Fine LJ, Cutler JA. Hypertension and the treating physician: understanding and reducing therapeutic inertia. Hypertension 2006; 47: 319–20.
    OpenUrlFREE Full Text
  15. ↵
    Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press, Institute of Medicine; 2001.
  16. ↵
    Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia (PA): WB Saunders Co; 1985.
  17. ↵
    Crabtree BF, Miller WL. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications; 2000.
  18. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886–92.
    OpenUrlCrossRefPubMedWeb of Science
  19. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertension 1996; 9: 342–60.
    OpenUrlCrossRefPubMedWeb of Science
  21. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401–9.
    OpenUrlCrossRefPubMedWeb of Science
  22. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091–6.
    OpenUrlAbstract/FREE Full Text
  23. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.
    OpenUrlCrossRefPubMedWeb of Science
  24. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 2000; 18: 1671–5.
    OpenUrlCrossRefPubMedWeb of Science
  25. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431–6.
    OpenUrlAbstract/FREE Full Text
  26. Yui Y, Sumiyoshi T, Kodama K, et al. Nifedipine retard was as effective as angiotensin-converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res Clinic Exp 2004; 27: 449–56.
    OpenUrl
  27. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542–9.
    OpenUrlCrossRefPubMedWeb of Science
  28. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073–82.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Bergamo Nephrologic Diabetes Complications Trial Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
    OpenUrlCrossRefPubMedWeb of Science
  30. Pepine CJ, Handberg-Thurmond E, Marks RG, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32: 1228–37.
    OpenUrlCrossRefPubMedWeb of Science
  31. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
    OpenUrlAbstract/FREE Full Text
  32. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press 1993; 2: 312–21.
    OpenUrlPubMed
  33. ↵
    Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996; 39: 1554–61.
    OpenUrlCrossRefPubMedWeb of Science
  34. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
    OpenUrlAbstract/FREE Full Text
  35. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
    OpenUrlCrossRefPubMedWeb of Science
  36. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23(Suppl 2): B54–B64.
    OpenUrl
  37. ↵
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M. Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus–a randomized prospective study. Diabet Med 2002; 19: 385–92.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Culos-Reed SN, Rejeski WJ, McAuley E, Ockene JK, Roter DL. Predictors of adherence to behavior change interventions in the elderly. Control Clin Trials 2000; 21(5 Suppl): 200S–205S.
    OpenUrl
  40. ↵
    Robiner WN. Enhancing adherence in clinical research. Contemp Clin Trials 2005; 26: 59–77.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    MaDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2003; 288: 2868–79.
    OpenUrl
  42. ↵
    Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care. 2001; 24: 1821–33.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Boulware LE, Daumit GL, Frick KD, Minkovitz CS, Lawrence RS, Powe NR. An evidence-based review of patient-centered behavioral interventions for hypertension. Am J Prev Med 2001; 21: 221–32.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479–86.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    Kravitz RL, Bell RA, Azari R, Krupat E, Kelly-Reif S, Thom D. Request fulfillment in office practice: antecedents and relationship to outcomes. Med Care 2002; 40: 38–51.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    Greenfield S, Kaplan SH, Ware JE Jr, Yano EM, Frank HJ. Patients’ participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med 1988; 3: 448–57.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    Oliveria SA, Chen RS, McCarthy BD, Davis CC, Hill MN. Hypertension knowledge, awareness, and attitudes in a hypertensive population. J Gen Intern Med 2005; 20: 219–25.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    Oettingen G, Mayer D. The motivating function of thinking about the future: expectations versus fantasies. J Pers Soc Psychol 2002; 83: 1198–212.
    OpenUrlCrossRefPubMedWeb of Science
  49. Oettingen G, Pak H, Schnetter K. Self-regulation of goal setting: turning free fantasies about the future into binding goals. J Pers Soc Psychol. 2001; 80: 736–53.
    OpenUrlCrossRefPubMedWeb of Science
  50. Heisler M, Vijan S, Anderson RM, Ubel PA, Bernstein SJ, Hofer TP. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? J Gen Intern Med 2003; 18: 893–902.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    Von Korff M, Glasgow RE, Sharpe M. Organising care for chronic illness. BMJ 2002; 325: 92–4.
    OpenUrlFREE Full Text
  52. ↵
    Lorig K. Action planning: a call to action. J Am Board Fam Med. 2006; 19: 324–5.
    OpenUrlFREE Full Text
  53. ↵
    Locke EA, Latham GP. Building a practically useful theory of goal setting and task motivation. A 35-year odyssey. Am Psychol 2002; 57: 705–17.
    OpenUrlCrossRefPubMedWeb of Science
  54. Naik AD, Schulman-Green D, McCorkle R, Bradley EH, Bogardus ST. Will older persons and their clinicians use a shared decision making instrument? J Gen Intern Med 2005; 20: 640–3.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    Handley M, MacGregor K, Schillinger D, Sharifi C, Wong S, Bodenheimer T. Using action plans to help primary care patients adopt healthy behaviors: a descriptive study. J Am Board Fam Med 2006; 19: 224–31.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Estabrooks PA, Nelson CC, Xu S, et al. The frequency and behavioral outcomes of goal choices in the self-management of diabetes. Diabetes Educ 2005; 31: 391–400.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Funnell MM, Nwankwo R, Gillard ML, Anderson RM, Tang TS. Implementing an empowerment-based diabetes self-management education program. Diabetes Educ 2005; 31: 53, 55–6, 61.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    Mandelblatt J, Kreling B, Figeuriedo M, Feng S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? J Clin Oncol 2006; 24: 4908–13. Epub 2006 Sept 18.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    MacGregor K, Handley M, Wong S, et al. Behavior-change action plans in primary care: a feasibility study of clinicians. J Am Board Fam Med 2006; 19: 215–23.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section